Intrabeam radiotherapy system for adjuvant treatment of early breast cancer

  • Technology appraisal guidance
  • TA501
  • Published: 
Download guidance (PDF)

6 Recommendations for further data collection

6.1 Clinicians should enter details about all patients who choose to have the Intrabeam radiotherapy system for adjuvant treatment of early invasive breast cancer during breast-conserving surgical removal of the tumour in the NHS onto a national register. They should audit, review and document clinical outcomes locally, and consider the relationship between outcomes and patients' characteristics.

6.2 The data and clinical outcomes to be collected include:

  • histology of the cancer and patients' characteristics including: type, size and grade of the tumour; side of the body affected; lymph node status; oestrogen receptor status; progesterone receptor status; human epidermal growth factor receptor 2 status; and age of the patient

  • local recurrence

  • treatment after local recurrence

  • metastatic disease

  • disease-free survival

  • overall survival

  • adverse effects of treatment

  • health-related quality of life (including EQ‑5D).